Risk Reward – LBX Pharmacy Chain (603883.SS): Network Expansion and Improving Profitability to Drive Stock

Morgan Stanley has updated its risk-reward view on LBX Pharmacy Chain (603883.SS). In view of 3Q26 results, we cut our 2026-30 earnings estimates by 2-4% to reflect lower revenue and gross margin assumptions, and our price target and scenario values are down 2-3%. The price target moves to Rmb17.50 from Rmb18.00, with bull, base and bear case values of Rmb21.50, Rmb17.50 and Rmb7.80. We maintain an Overweight rating with an Attractive industry view. The stock closed at Rmb14.97 on Nov 6, 2026, implying 12.1x base case 2027e EPS. We forecast revenue and earnings CAGRs of 6% and 54% over 2025-28e off a very low 2025 base, driven by network expansion, margin improvement, prescription outflow and industry consolidation. At 10.3x 2027e P/E, the market underappreciates its growth prospects and position as a top five pharmacy chain in China. Key risks are slower network expansion, intensifying competition and weaker consumer demand.